Selbyville, DE -- (SBWIRE) -- 12/26/2018 -- Global Vaccines Market size is set to exceed USD 65 billion by 2024; according to a new research report by Global Market Insights, Inc.
Introduction of innovative technologies in vaccination, rising government support for product development will stimulate global vaccines market growth over the coming years. Growing awareness towards preventive vaccination in pediatric and increasing adoption of therapeutic vaccines in cancer treatment will fuel industry growth.
Increasing disease prevalence in underdeveloped countries coupled with growing incidence of cancer & HIV will serve as high impact rendering factor for the business growth. High cost and inadequate reimbursement coverage for vaccines will hamper industry expansion. Moreover, stringent government regulations for product approval will further restrain business growth.
Request sample copy of this report @ https://www.gminsights.com/request-sample/detail/2186
Pediatric will grow at a significant rate over the forecast period owing to CDC recommendation for immunization schedule to protect children and infants before getting exposed to potentially life-threatening diseases.
Attenuated vaccines will grow at a substantial rate over the forecast period pertaining to factors such as robust antibody and cellular responses, and frequently deliberate lifelong immunity with only one or two doses.
Influenza will witness considerable growth due to growing incidence, mounting number of disease-causing microbes (pathogens) and rising awareness in emerging economies towards disease prevention. Availability of vaccines at affordable prices in hospitals and clinics will augment the segment growth.
Make Inquiry about this report @ https://www.gminsights.com/inquiry-before-buying/2186
U.S. vaccines market will witness significant growth over the forecast period pertaining to enormous impact of immunization on improving health of children and protecting them with vaccines due to epidemics of preventable diseases like mumps, pertussis, and measles.
India will witness lucrative growth due to improved efficiency of immunization programs and technological advancements in vaccine storage and transport. Rising per capita income, improved healthcare infrastructure and growing healthcare expenditure will promote business growth.
China vaccines market will grow at a substantial rate owing to rising disposable income, rapid economic growth, rising number of unvaccinated migrant workers, and delivery of efficient healthcare services.
Brazil vaccines market will growth at a considerable rate over the coming years. Availability of vaccines at low cost and rising initiatives by Brazilian government to improve vaccination coverage will stimulate steady business expansion.
Some of the companies operating in industry are Abbott, AstraZeneca, Astellas Pharma, Bristol-Myers Squibb, CSL, Emergent BioSolutions, GlaxoSmithKline, Johnson & Johnson, Merck & Co., Novartis, Novavax, Pfizer and Sanofi Pasteur.
New product launches and expansion of existing product portfolio will mainly drive the business growth. Major industry participants will endeavor to fortify their market position by adopting these strategies.
Report Content
Chapter 1. Methodology
1.1. Methodology
1.1.1. Initial data exploration
1.1.2. Statistical modeling and forecast
1.1.3. Industry insights and validation
1.1.4. Market definition and forecast assumptions
1.2. Data sources
1.2.1. Primary
1.2.2. Secondary
Chapter 2. Executive Summary
2.1. Global Vaccines industry 3600 synopsis, 2013 - 2024
2.1.1. Business trends
2.1.2. Age group trends
2.1.3. Disease trends
2.1.4. Technology trends
2.1.5. Regional trends
Chapter 3. Vaccines Industry Insights
3.1. Industry segmentation
3.2. Industry landscape, 2013 – 2024
3.3. Industry impact forces
3.3.1. Growth drivers
3.3.1.1. Increasing government funding for vaccine development
3.3.1.2. Increasing vaccines R&D in developed nations
3.3.1.3. Increasing disease prevalence in underdeveloped countries
3.3.1.4. Growing incidences of cancer & HIV in Asia Pacific
3.3.2. Industry pitfalls & challenges
3.3.2.1. High cost of vaccine storage and transportation
3.3.2.2. Stringent regulations for the approval of vaccines in developed nations
3.4. Growth potential analysis
3.4.1. By age group
3.4.2. By technology
3.4.3. By disease
3.5. Regulatory landscape
3.5.1. U.S
3.5.2. Europe
3.5.3. Asia Pacific
3.6. Reimbursement scenario
3.6.1. U.S
3.6.2. Europe
3.7. Technology landscape
3.8. Pricing analysis
3.9. Pipeline product analysis
3.9.1. Malaria
3.9.2. HIV
3.9.3. Zika
3.9.4. Ebola
3.10. Porter's analysis
3.11. Company market share analysis, 2016
3.11.1. Strategy dashboard
3.12. PESTEL analysis